Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Chief Operations Officer | November 16, 2021 | November 18, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date November 16, 2021 · Filed November 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 113,097 |
Reported balance
After 2021-11-16 transaction · row 1
1 source rowRow 1 · 2021-11-16 · Sale · Disposed 3,332 · Balance 113,097 F1: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. The prices actually received ranged from $16.45 to $17.3823. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold on behalf of the group at each price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units.
F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. The prices actually received ranged from $16.45 to $17.3823. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold on behalf of the group at each price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 16, 2021 Filed Nov 18, 2021 22:54 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,332 | $17.12 | $57,033.51 |
DisclosureSEC source: 0001567619-21-020780 · doc1.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,097 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. The prices actually received ranged from $16.45 to $17.3823. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold on behalf of the group at each price within the range. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 21:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 708 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001567619-21-020653 · doc1.xml · derivative · entry 4 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,917 Underlying: Common Stock · 708 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. F3 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 21:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,792 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001567619-21-020653 · doc1.xml · derivative · entry 3 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,083 Underlying: Common Stock · 2,792 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. F3 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 21:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 7,000 | $17.71 | $124,004.30 |
DisclosureSEC source: 0001567619-21-020653 · doc1.xml · nonDerivative · entry 2 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,429 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $17.62 to $17.85. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 21:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 3,500 | $12.15 | $42,525.00 |
DisclosureSEC source: 0001567619-21-020653 · doc1.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 21:35 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,125 | $17.00 Strike: $12.15 | $36,125.00 |
DisclosureSEC source: 0001567619-21-017578 · doc1.xml · derivative · entry 4 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,625 Underlying: Common Stock · 2,125 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. F2 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 21:35 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 8,375 | $17.00 Strike: $12.15 | $142,375.00 |
DisclosureSEC source: 0001567619-21-017578 · doc1.xml · derivative · entry 3 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,875 Underlying: Common Stock · 8,375 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. F2 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 21:35 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 10,500 | $17.00 | $178,500.00 |
DisclosureSEC source: 0001567619-21-017578 · doc1.xml · nonDerivative · entry 2 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,929 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 21:35 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 10,500 | $12.15 | $127,575.00 |
DisclosureSEC source: 0001567619-21-017578 · doc1.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:36 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,116 | $15.61 | $48,647.30 |
DisclosureSEC source: 0001567619-21-017260 · doc1.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,929 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.54 to $15.73. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 30, 2021 Filed Aug 31, 2021 21:05 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,500 | $15.00 | $52,500.00 |
DisclosureSEC source: 0001567619-21-016517 · doc1.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,045 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 23:36 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,426 | $12.53 | $30,402.63 |
DisclosureSEC source: 0001567619-21-016150 · doc1.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,545 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 17, 2021 and August 18, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| May 18, 2021 Filed May 20, 2021 20:33 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,453 | $14.55 | $35,691.15 |
DisclosureSEC source: 0001209191-21-034430 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,971 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 18, 2021 and May 19, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| May 17, 2021 Filed May 17, 2021 22:32 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,500 | $15.00 | $52,500.00 |
DisclosureSEC source: 0001209191-21-033285 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,424 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:36 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 655 | $14.74 | $9,654.70 |
DisclosureSEC source: 0001209191-21-025888 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,924 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| March 26, 2021 Filed Mar 30, 2021 21:18 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,640 | $14.58 | $38,491.20 |
DisclosureSEC source: 0001209191-21-023583 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,579 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.437 to $14.58. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 15, 2021 Filed Mar 15, 2021 23:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 709 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001209191-21-020578 · doc4.xml · derivative · entry 4 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,750 Underlying: Common Stock · 709 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. F3 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service. Read SEC document |
| March 15, 2021 Filed Mar 15, 2021 23:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,791 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001209191-21-020578 · doc4.xml · derivative · entry 3 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,250 Underlying: Common Stock · 2,791 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. F3 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service. Read SEC document |
| March 15, 2021 Filed Mar 15, 2021 23:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 7,000 | $17.41 | $121,870.00 |
DisclosureSEC source: 0001209191-21-020578 · doc4.xml · nonDerivative · entry 2 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,219 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $17.01 to $17.59. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 15, 2021 Filed Mar 15, 2021 23:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 3,500 | $12.15 | $42,525.00 |
DisclosureSEC source: 0001209191-21-020578 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:08 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,665 | $16.74 | $27,872.10 |
DisclosureSEC source: 0001209191-21-017773 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,719 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2021 and March 3, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 56,929 | $0.00 Strike: $17.11 | $0.00 |
DisclosureSEC source: 0001209191-21-017040 · doc4.xml · derivative · entry 2 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,929 Underlying: Common Stock · 56,929 shares Expires 2031-02-28 F2 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2021, subject to the reporting person's continuous service. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 37,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017040 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,384 F1 · shares: These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2021, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 00:59 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,886 | $20.39 | $79,235.54 |
DisclosureSEC source: 0001209191-21-009054 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,669 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 8, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 354 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001209191-21-003996 · doc4.xml · derivative · entry 4 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,459 Underlying: Common Stock · 354 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. F3 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,146 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001209191-21-003996 · doc4.xml · derivative · entry 3 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,041 Underlying: Common Stock · 3,146 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. F3 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 7,000 | $18.84 | $131,880.00 |
DisclosureSEC source: 0001209191-21-003996 · doc4.xml · nonDerivative · entry 2 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,555 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $18.36 to $19.125. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 21:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 3,500 | $12.15 | $42,525.00 |
DisclosureSEC source: 0001209191-21-003996 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 23:35 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 354 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001209191-20-064504 · doc4.xml · derivative · entry 5 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,813 Underlying: Common Stock · 354 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. F2 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 23:35 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,146 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001209191-20-064504 · doc4.xml · derivative · entry 4 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,187 Underlying: Common Stock · 3,146 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. F2 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 23:35 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,500 | $23.08 | $80,780.00 |
DisclosureSEC source: 0001209191-20-064504 · doc4.xml · nonDerivative · entry 3 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,055 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 23:35 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,500 | $23.13 | $80,955.00 |
DisclosureSEC source: 0001209191-20-064504 · doc4.xml · nonDerivative · entry 2 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,555 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 23:35 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 3,500 | $12.15 | $42,525.00 |
DisclosureSEC source: 0001209191-20-064504 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 21:07 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,648 | $19.77 | $32,587.55 |
DisclosureSEC source: 0001209191-20-059046 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,555 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 17, 2020 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| November 13, 2020 Filed Nov 16, 2020 21:19 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 667 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001209191-20-058464 · doc4.xml · derivative · entry 5 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,333 Underlying: Common Stock · 667 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. F4 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service. Read SEC document |
| November 13, 2020 Filed Nov 16, 2020 21:19 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,833 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001209191-20-058464 · doc4.xml · derivative · entry 4 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,167 Underlying: Common Stock · 2,833 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. F4 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service. Read SEC document |
| November 13, 2020 Filed Nov 16, 2020 21:19 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,300 | $19.12 | $24,856.00 |
DisclosureSEC source: 0001209191-20-058464 · doc4.xml · nonDerivative · entry 3 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,203 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. F3 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $18.85 to $19.18. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 13, 2020 Filed Nov 16, 2020 21:19 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 6,200 | $18.36 | $113,832.00 |
DisclosureSEC source: 0001209191-20-058464 · doc4.xml · nonDerivative · entry 2 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,503 F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. F2 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $17.84 to $18.74. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 13, 2020 Filed Nov 16, 2020 21:19 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionCommon Stock | 3,500 | $12.15 | $42,525.00 |
DisclosureSEC source: 0001209191-20-058464 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. Read SEC document |
| November 13, 2020 Filed Dec 18, 2020 23:32 UTC Amendment | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,833 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001209191-20-064501 · doc4a.xml · derivative · entry 2 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,167 Underlying: Common Stock · 2,833 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. F2 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service. Read SEC document |
| November 13, 2020 Filed Dec 18, 2020 23:32 UTC Amendment | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 667 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001209191-20-064501 · doc4a.xml · derivative · entry 1 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,333 Underlying: Common Stock · 667 shares Expires 2030-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020. F2 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 23:37 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,678 | $12.09 | $20,287.02 |
DisclosureSEC source: 0001209191-20-047819 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,203 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 18, 2020 and August 19, 2020 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| May 18, 2020 Filed May 20, 2020 22:11 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,603 | $11.22 | $17,985.66 |
DisclosureSEC source: 0001209191-20-031007 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,881 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 18, 2020 and May 19, 2020 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| April 06, 2020 Filed Apr 7, 2020 20:21 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 657 | $7.94 | $5,216.58 |
DisclosureSEC source: 0001209191-20-023763 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,484 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| March 27, 2020 Filed Mar 30, 2020 20:05 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,740 | $9.17 | $25,125.80 |
DisclosureSEC source: 0001209191-20-021698 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,141 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 22:00 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001209191-20-015351 · doc4.xml · derivative · entry 3 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2030-02-28 F2 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 22:00 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 53,000 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001209191-20-015351 · doc4.xml · derivative · entry 2 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 Underlying: Common Stock · 53,000 shares Expires 2030-02-28 F2 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 22:00 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015351 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,881 F1 · shares: These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2020, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year. Read SEC document |
| February 06, 2020 Filed Feb 11, 2020 00:48 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 4,117 | $14.21 | $58,502.57 |
DisclosureSEC source: 0001209191-20-008126 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,881 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| September 27, 2019 Filed Sep 30, 2019 20:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,500 | $13.51 | $47,285.00 |
DisclosureSEC source: 0001209191-19-051095 · doc4.xml · nonDerivative · entry 1 Newell Joe · CIK 0001702457 · Chief Tech. Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,998 F1 · price: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $13.50 to $13.52. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.